anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Carotid artery revascularization has traditionally been performed by either a carotid endarterectomy or carotid artery stent. Large data analysis has suggested there are differences in perioperative outcomes with regards to race, with non-White patients (NWP) having worse outcomes of stroke, restenosis and return to the operating room (RTOR). The introduction of transcarotid artery revascularization (TCAR) has started to shift the paradigm of carotid disease treatment. However, to date, there have been no studies assessing the difference in postoperative outcomes after TCAR between racial groups.
METHODS: All patients from 2016 to 2021 in the Vascular Quality Initiative who underwent TCAR were included in our analysis. Patients were split into two groups based on race: individuals who identified as White and a second group that comprised all other races. Demographic and clinical variables were compared using Student's t-Test and chi-square test of independence. Logistic regression analysis was performed to determine the impact of race on perioperative outcomes of stroke, myocardial infarction (MI), death, restenosis, RTOR, and transient ischemic attack (TIA).
RESULTS: The cohort consisted of 22,609 patients: 20,424 (90.3%) White patients and 2185 (9.7%) NWP. After adjusting for sex, diabetes, hypertension, coronary artery disease, history of prior stroke or TIA, symptomatic status, and high-risk criteria at time of TCAR, there was a significant difference in postoperative stroke, with 63% increased risk in NWP (odds ratio = 1.63, 95% confidence interval: 1.11-2.40, P = 0.014). However, we found no significant difference in the odds of MI, death, postoperative TIA, restenosis, or RTOR when comparing NWP to White patients.
CONCLUSIONS: This study demonstrates that NWP have increased risk of stroke but similar outcomes of death, MI, RTOR and restenosis following TCAR. Future studies are needed to elucidate and address the underlying causes of racial disparity in carotid revascularization.
Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
To take out elastin from marine arterial spheres of tuna and others by effectively using the enzyme of bromelain.SOLUTION: By using the aqueous solution obtained from the tuna arterial sphere as a raw material, hydrolyzed elastin can be obtained from artery spheres. Bromelain in an amount of 1 to 10% of arterial spheres is mixed with the arterial spheres and weighed. About 10% of propylene glycol and 1 to 10% of 1,2 hexanediol in an amount of the total amount are mixed and soaked for 1 to 60 minutes. Thereafter, 2 to 10 times the volume of purified water is added, and the mixture is incubated for 5 to 12 hours in a temperature range of about 40 to 60°C, thereby the activated bromelain protease eluting elastin from the flesh part of the arterial sphere. The subject is solved by obtaining it by raising the temperature above 80°C and inactivating bromelain protease in 10-20 minutes. The resulting water-soluble elastin contains elastin-specific amino acids, desmosine and isodesmosine.SELECTED DRAWING: Figure 1
Osteopathic Sham treatment was applied using manual contact on specific bony surfaces using very light pressure. The practitioner was counting the seconds up to 1 minute between the areas where to apply the light touch without any intention to treat or diagnose.
Patients receive NBTXR3 IT or IN on day 1. Beginning day 15, patients undergo IMRT 5 days per week for 6 weeks for a total of 28 fractions, in the absence of disease progression or unacceptable toxicity. Concurrent with IMRT, patients receive a chemotherapy regimen consisting of either fluorouracil and oxaliplatin with or without leucovorin, oxaliplatin and capecitabine, docetaxel and fluorouracil with or without leucovorin, docetaxel and paclitaxel, or carboplatin and paclitaxel per physician discretion.
Patients randomized to the control group will receive standard medical care, including nutritional care as provided by the center in usual care. Additionally, they receive an activity tracker (like the intervention group) but without specific instructions. We will provide the control patients with written advice on physical activity and diet according to the current guidelines (in short: to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150 min/week).
Bariatric surgery (BS) is considered the most effective intervention for patients with severe obesity and is used to maintain long-term weight loss and glycemic control. The aim of this study was to analyze the effects of genotypes and haplotypes of the fat mass and obesity-associated (FTO) and melanocortin 4 receptor (MC4R) genes on total body weight loss (TBWL), post-surgery weight, and post-BMI after bariatric surgery. We retrospectively selected 101 patients from Bajio High Specialty Regional Hospital, León Guanajuato, México, who underwent Roux-en-Y gastric bypass (RYGB) to determine their body mass index (BMI), blood pressure, biochemical characteristics, and comorbidities. Post-surgery, patients were referred for registered anthropometry and blood pressure. Glucose, lipid and hepatic profiles, and insulin, leptin, and ghrelin levels were measured, and rs9939609, rs9930506, and rs1421085 FTO and rs17782313 MC4R polymorphisms were genotyped. Six (4-8) years after BS, post-surgery weight was greater in carriers of the rs9939609 and rs1421085 risk genotypes. TBWL was lower for the rs9930506 and rs1421085 risk genotypes. Insulin and HOMA-IR were greater in patients with the three FTO polymorphisms. There were significant interaction effects of the rs9930506 and rs1421085 FTO risk genotypes on weight and BMI in response to BS. No association was found with the MC4R polymorphism. The genotypes and haplotypes of the FTO gene influence post-surgery weight, TBWL, insulin levels, and HOMA-IR.
For all subjects, administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan. Data collection will start about 10 min before the administration of oxygen, and last throughout the oxygen exposure, then continue for about 10 min after oxygen exposure for each subject.
Participants will receive ezetimibe/atorvastatin 10/40 mg QD from Visit 2 (Day 1) to Visit 3 (Week 6). If the LDL-C target is reached (LDL-C \< 55 mg/dL) at Visit 3, maintain the dose to Visit 4 (Week 12). If the LDL-C target level is not reached at Visit 3, dose is increased to ezetimibe/atorvastatin 10/80 mg QD from Visit 3 to Visit 4.
Preparations containing aspirin should be kept out of the reach of children. Reye's Syndrome is a rare condition that affects the brain and liver and is most often observed in children given aspirin during a viral illness. Safety and effectiveness in pediatric patients have not been established.

The safety and effectiveness of ASCOMP with Codeine in pediatric patients have not been established.

Life-threatening respiratory depression and death have occurred in children who received codeine [see Warnings and Precautions (5.6)]. In most of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects of codeine. Because of the risk of life-threatening respiratory depression and death:

  * ASCOMP with Codeine is contraindicated for all children younger than 12 years of age [see Contraindications (4)].
  * ASCOMP with Codeine is contraindicated for post-operative management in pediatric patients younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Contraindications (4)].
  * Avoid the use of ASCOMP with Codeine in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks. Risk factors include conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression [see Warnings and Precautions (5.6)].
The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells. The reagent and pharmaceutical formulation of the invention relates to Na + /K + -ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.
OBJECTIVE: The present study aims to investigate the specific protective effects and underlying mechanisms of Ganshuang granule (GSG) on dimethylnitrosamine (DMN)-induced hepatic fibrosis in rat models.
METHODS: Hepatic fibrosis was experimentally evoked in rats by DMN administration, and varying dosages of GSG were employed as an intervention. Hepatocellular damage was assessed by measuring serum levels of aminotransferase and bilirubin, accompanied by histopathological examinations of hepatic tissue. The hepatic concentrations of platelet-derived growth factor (PDGF) and transforming growth factor-β1 (TGF-β1) were quantitated via enzyme-linked immunosorbent assay (ELISA). The expression of α-smooth muscle actin (α-SMA) within hepatic tissue was evaluated using immunohistochemical techniques. The levels of hepatic interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and a spectrum of interleukins (IL-2, IL-4, IL-6, IL-10) were quantified by quantitative real-time PCR (qRT-PCR). Additionally, hepatic stellate cells (HSCs) were cultured in vitro and exposed to TNF-α in the presence of naringin, a principal component of GSG. The gene expression levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and matrix metallopeptidase-1 (MMP-1) in these cells were also quantified by qRT-PCR. Proliferative activity of HSCs was evaluated by the Cell Counting Kit-8 assay. Finally, alterations in Smad protein expression were analyzed through Western blotting.
RESULTS: Administration of GSG in rats with fibrosis resulted in reduced levels of serum aminotransferases and bilirubin, along with alleviation of histopathological liver injury. Furthermore, the fibrosis rats treated with GSG exhibited significant downregulation of hepatic TGF-β1, PDGF, and TNF-α levels. Additionally, GSG treatment led to increased mRNA levels of IFN-γ, IL-2, and IL-4, as well as decreased expression of α-SMA in the liver. Furthermore, treatment with naringin, a pivotal extract of GSG, resulted in elevated expression of MMP-1 and decreased levels of TIMP-1 in TNF-α-stimulated HSCs when compared to the control group. Additionally, naringin administration led to a reduction in Smad expression within the HSCs.
CONCLUSION: GSG has the potential to mitigate fibrosis induced by DMN in rat models through the regulation of inflammatory and fibrosis factors. Notably, naringin, the primary extract of GSG, may exert a pivotal role in modulating the TGF-β-Smad signaling pathway.
In population Ⅳ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅳ population were injected High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02).The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
Participants are randomized to vape one out of the eight study e-liquids in a 10-puff vaping session over 5 minutes using the e-cig study device and then in an ad libitum puffing session over 60 minutes. The 8 e-liquids vary in nicotine concentration (low \[20 mg/g\] or high \[50 mg/g\]), form (Nic or NicH+), and isomer (S-nicotine or R/S nicotine).
Participants randomised to the self-acupuncture arm will be asked to attend a group workshop. All participants will be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total). Participants will be asked to needle the points 2-3 times a week throughout their cancer treatment and for 3 months post treatment.
Educational content based on the health promotion model, including nutrition and physical activity, will be created by the researcher by scanning the literature and considering the needs of the students. For the nutrition and physical activity plans included in the training, a diet specialist and a sports specialist will be consulted on the subject. The created training content and the booklet will be submitted to the opinion of at least three experts who are suitable for the subject area. Educational content deemed appropriate will be shared with students for 1 lesson per week for 10 weeks.
For expansion part, specific tumor types are recruited (non-small cell lung cancer (NSCLC) and gastric/gastroesophageal junction (GEJ) adenocarcinoma). BAY2965501 will be taken in combination with 200mg pembrolizumab every 3 weeks.
The present invention relates to the use of an ECM-altering enzymatic activity, such as a proteoglycanase or a protease, to stimulate the generation of cartilage tissue by inducing chondrocytes to synthesize new cartilage matrix. It has been discovered that treating chondrocytes with an enzymatic activity that modifies the territorial ECM of the cell, especially cell surface proteoglycans, can in and of itself be sufficient to stimulate cartilage production by the chondrocytes. The subject invention can be employed therapeutically to correct or prevent degeneration of connective tissue. For instance, the present method can be used in the treatment of disorders comprising cartilage such as found in an diarthroidal joint (e.g. articular and interarticular cartilage), as well as in the treatment of tendon and ligamental tissues. Such disorders can range from chronic degeneration brought about by disease, overuse, or trauma, to plastic or reconstructive surgery. Moreover, the subject method may also be applied to both the development and implantation of prosthetic devices.
A system operable to transmit healthcare data to a user device configured for use in analysing medical information. A directed graph representing at least one medical guideline is maintained in a database. The directed graph includes a plurality of nodes connected by a plurality of directed edges. In some examples a directed graph is selected based on a medical condition and a context parameter. In some examples a directed graph is generated based on differences between versions of medical guidelines. A patient model may be maintained in a database and in some examples based on a combination of the directed graph and the patient model, further healthcare data is transmitted to the user device. The status of nodes and edges may be determined based on a combination of a directed graph and a patient model.
A computer screen or application method configured to provide alterations of the color of the screen or application window based upon the detected mood of the computer user. The present invention employs facial mapping utilizing suitable techniques to capture the facial image of the computer user. During use of the software application of the present invention the computer users face is consistently mapped and analyzed in order to detect expression changes. The present invention will determine the potential mood of the computer user based on the facial expression analysis. Ensuing determination of the mood of the computer user, the present invention will change the color of computer screen or an application window displayed thereon. The color change is directed to either maintain a potential mood or alter the mood of the computer user. The present invention executes constant analysis and color changes based on the consistent mapping.
Male clients, aged 19 to 44 years, coming to the gym for strength training will be purposively selected based on the inclusion criteria and then randomly assigned into two groups. They will undergo a series of pre-intervention tests that would assess their strength using Bourbon TMS and standing long jump tests; flexibility using stand and reach test; balance using Y balance test; coordination using jumping sideways test and speed using 20-m sprint test. After initial assessment, they will be advised and demonstrated for curl-up, side-bridging and quadrupled exercises. The experimental group will perform these exercises on Thera-Band© Exercise Ball while the control group will perform the same exercises on gym floor. The clients will have sessions on preferably the first day and 4th day of the week but is subject to their attendance at the gym. There will be interval assessments at 2nd and 4th week based on the tests mentioned above to record changes at these intervals. After 6 weeks of bi-weekly sessions, the clients will undergo post-intervention tests that will be the same as pre-intervention tests.
SUPPRELIN LA (NDC 67979-002-01) is supplied in a corrugated shipping carton that contains 2 inner cartons: a small one for the vial containing the SUPPRELIN LA implant, which is shipped with a cold pack inside a polystyrene cooler that must be refrigerated upon arrival, and a larger one comprising the Implantation Kit, which must not be refrigerated, for use during insertion or removal of SUPPRELIN LA.

The SUPPRELIN LA implant contains 50 mg of histrelin acetate. The SUPPRELIN LA implant carton contains a cold pack for refrigerated shipment and a small carton containing an amber plastic pouch. Inside the pouch is a glass vial with a Teflon-coated stopper and an aluminum seal, containing the implant in 2 mL of sterile 1.8% sodium chloride solution. (Note: The 3.5 mL vial is not completely filled with saline). 

Upon receipt, refrigerate the small carton containing the amber plastic pouch and glass vial (with the implant inside) until the day of insertion. The implant vial should not be opened until just before the time of insertion.

SUPPRELIN LA is stable when stored refrigerated, in its sealed vial, pouch, and carton, at 2-8 °C (36-46 °F) until the expiration date provided. Excursion permitted to 25 °C (77 °F) for 7 days. Do not freeze. Protect from light.
Single dose: 3 tablets (384 mg). Multiple dose: 3 tablets (384 mg) 3 times a day for 3 days (the first intake of the drug on an empty stomach, the second and third - two hours after a meal), once in the morning on an empty stomach on the 4th day.
PURPOSE: To enable highly advanced clinical diagnosis and treatment such as an immuno assay or the like by using an antibody derived from a no-antigen animal as an antibody. CONSTITUTION: A germ-free animal is obtained by germ-free cesarean section or germ-free eclosion, and bred by germ-free technique under the isolator condition. As a germ-free animal, a mouse, a pig, a rat and so on are general, and Balb/c mouse among mouses is preferable. By using a germ-free system, a monoclonal antibody to all antigens which a non-germ free animal produces can be produced. As the germ-free animal shows a strong immune response to antigen, it is possible to heighten the probability of ascertaining B-lymphocyte which produces antibody connected to a specific epitope of antibody. Furthermore, it is possible to produce highly specific antibody to antigen having many epitopes. The thus obtained monoclonal antibody is mainly used in immuno assay which is measurement for antigen-antibody interaction, and also used as an in vivo image formation and treatment agent.
ASA 1 and 2 full term (37-42 weeks), parturients with singleton pregnancy, normal placental position, scheduled for category 4 LSCS under 'single-shot' spinal anaesthesia will be recruited. The investigators intend to recruit 60 parturients. The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. A patient information leaflet will be provided for the parturients.
PROBLEM TO BE SOLVED: To obtain the subject safe pharmaceutical preparation excellent in solubility of a sparingly soluble immunosuppressant in water and capable of manifesting excellent pharmacological effects by including the sparingly soluble immunosuppressant, a phospholipid and a liquid paraffin. SOLUTION: This O/W emulsion pharmaceutical preparation (preferably an eye drop, an ear drop, etc.), is obtained by including (A) a sparingly soluble immunosuppressant (preferably a cyclosporin), (B) a phospholipid, (C) a liquid paraffin and (D) water. The amount of the ingredient B used is preferably 5-50 pts.wt. based on 1 pt.wt. of the ingredient A and the amount of the ingredient C used is preferably 0.5-5 pts.wt. based on 1 pt.wt. of the ingredient B.  The O/W emulsion is prepared by dissolving the phospholipid such as egg yolk lecithin and the sparingly soluble immunosuppressant in a suitable organic solvent such as hexane under stirring, then distilling off the solvent, forming a phospholipid thin film, adding the liquid paraffin, distilled water, etc., to the formed thin film, carrying out the preemulsification, subsequently emulsifying the resultant preemulsion with an emulsifier and regulating the prepared emulsion to objective pH (preferably 5-9).
ABSTRACT         The invention relates to a therapeutically active enzyme which is an odorless, white powder, the pH of a 15,000 to 22,000 IU/ml. solution of which in carbon dioxide-free physiological saline solution suitable for injection is 4.5 to 7.5, the solution being clear and colorless; a solution of 50,000 IU of which in 3 ml.  carbon dioxide-free physiological saline solution suitable for injection has a light absorption of not more than 0.60 at 280 nm. and of not more than 0.37 at 260 nm.; the enzyme having the following percentage amino acid analyzis:       The enzyme further has a total hexose content of 10.6 ? 0.003%, contains not more than 5 µg. albumin per 220,000 KU of activity and has a molecular weight of 62,000 to 70,000 determined by gel infiltration and a specific activity of at least 30,000 IU/mg.  The enzyme of the invention is useful as an aid to the survival of myocardial tissue after infarction and is also useful for the treatment of peripheral vascular disease.
The present invention relates generally to the treatment of patients and products for treating patients. More specifically, the present invention relates to enteral solution for providing nutritional support to patients. Nutritional solutions and methods of making same are disclosed. The embodiment of the invention is a nutritional product comprising: a protein source; a lipid source; and a carbohydrate source including high amylose starch and guar gum. Another embodiment is a nutritional product comprising: a hydrolyzed whey protein source; a source of lipids; and a sufficient amount of a stabilizer to reduce serum separation, the stabilizer including high amylase starch and guar gum. Yet another embodiment is a nutritional product comprising: a hydrolyzed whey protein source; a source of lipids; and a sufficient amount of a stabilizer to reduce serum separation, the stabilizer including carrageenan, starch and guar gum. The invention also provides a method of stabilizing an enteral solution comprising the steps of adding to an enteral solution a stabilizing amount of high amylose starch and guar gum.